In a report released today, A.J. Rice from Credit Suisse reiterated a Hold rating on Cano Health (CANO – Research Report), with a price target of $2.50. The company’s shares closed yesterday at $1.28.
According to TipRanks, Rice is a 5-star analyst with an average return of 9.7% and a 59.79% success rate. Rice covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, ACADIA Pharmaceuticals, and Amedisys.
Cano Health has an analyst consensus of Hold, with a price target consensus of $2.43, representing an 89.84% upside. In a report released on May 9, UBS also maintained a Hold rating on the stock with a $1.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $9.75 and a one-year low of $0.76. Currently, Cano Health has an average volume of 6.16M.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CANO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jaws Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
Read More on CANO:
- Cano Health Announces Financial Results for the First Quarter 2023
- Cano Health Opens Three New Medical Centers in South Florida
- Cano Health opens three new medical centers in FL
- Cano Health announces separation of Chairman and CEO roles
- Cano Health: Shareholders urge company reopen window for nominating directors
